PathLEAD: Pathology image data Lake for Education, Analytics and Discovery.

“Path LEAD(**Path**ology Data**L**AKES，**E**Education，**A**Analytics and**D**iscovery)是一个由来自考文垂、贝尔法斯特、诺丁汉和牛津的教学医院、相关大学和商业合作伙伴飞利浦的全国领先专家组成的联盟。我们将开发用于病理样本测试的计算机辅助诊断。目前，专科医生(称为病理学家)通过在显微镜下对病理标本进行肉眼检查来进行测试，这一过程本身就是主观的。很大一部分被检查的组织样本是正常的，使用专家病理学家的时间来确定这一点是昂贵的。我们相信这可以由计算机来完成，这样可以节省宝贵的病理学家时间并在其他地方使用。因此，我们将开发一个能够识别正常组织的计算机程序，这样样本就不需要病理学家检查了。此外，我们知道病理学家的表现是多种多样的，在某些情况下是有限的，特别是在他们执行的任务复杂或需要广泛经验的情况下。这可能意味着患有某些形式的乳腺癌和前列腺癌的患者得不到最好的治疗。我们的计算机程序将帮助病理学家改进这些决定。这些工具的开发需要从扫描显微镜载玻片获得数千个图像文件。收集这些数据非常耗时，因此一旦产生这些数据，它就是一种宝贵的资源。我们的目标是将其提供给其他研究团队、我们的商业合作伙伴飞利浦和开发工具以改善医疗保健的英国公司。其结果将是更多的知识、更好的工具和对未来更好的关怀。我们认识到患者有权不允许他们的数据被用于此目的，并将使用最近推出的NHS国家数据选择退出计划来准确记录患者的意愿。患者和我们道德和管理委员会的非专业代表将帮助决定如何使用这些数据。我们预计一些工具将在商业上取得成功，并计划利用这一成功将部分收入重新投资到NHS，使患者受益。我们提供高质量数据、专业知识、访问顶级计算机设备以及将这些工具商业化的知识的能力，将渗透到英国公司，建设这一领域的经济，并使英国成为全球领导者。我们的专业知识将为病理学和计算机科学界提供教育，分享所获得的知识，提高质量和效率，并将患者的利益作为我们的最终目标。

"PathLEAD (**Path**ology data **L**akes, **E**ducation, **A**nalytics and **D**iscovery) is a consortium of nationally leading experts from the teaching hospitals of Coventry, Belfast, Nottingham and Oxford, their associated Universities and Philips, the commercial partner. We will develop computer aided diagnostics for testing of pathology samples. Specialist doctors (called pathologists) currently carry out testing via visual examination of pathology specimens under the microscope, a process that is inherently subjective. A large proportion of tissue samples examined are normal and using specialist pathologist time to establish this is expensive. We believe this can be done by computers, and valuable pathologist time saved and used elsewhere. Therefore we will develop a computer programme that will recognise normal tissue so that the sample does not need to examined by the pathologist. Furthermore we know that pathologists' performance is variable and in some cases limited, particularly where the tasks they perform are complex or require extensive experience. This can mean patients with some forms of breast and prostate cancer do not get the best treatment. Our computer programmes will assist the pathologist and improve these decisions. The development of these tools requires thousands of image files obtained from scanning microscope slides. This is time consuming to collect so once this data has been produced it is a valuable resource. We aim to make this available to other research teams, our commercial partner Philips and UK-based companies developing tools to improve healthcare. The result will be greater knowledge, improved tools and better care for the future. We recognise that patients have the right not to allow their data to be used for this purpose, and will be using the recently launched NHS National Data Opt Out scheme to record patients wishes accurately. Patients and lay representatives on our ethical and management committee will help decide how this data should be used.We expect that some tools will become successful commercially and plan to exploit this success re-investing some of the income back into the NHS to benefit patients.Our ability to provide high quality data, expertise, access to top-grade computer equipment and knowledge of commercialising these tools, will percolate to UK companies, building the economy in this sector and lead to the UK becoming a global leader.Our expertise will provide education to the pathology and computer science communities to share the knowledge gained, gaining in quality and efficiency, and having patients' benefit as our ultimate goal."